UK High Court of Justice Rules Endocuff® and Endocuff Vision® Patents and Design Rights to be Valid and Infringed

Amsterdam (ots/PRNewswire) -

Arc Medical Design Limited, a subsidiary of Norgine B.V., today
announced that the High Court of Justice England and Wales, Patents
Court ruled that ENDOCUFF® and ENDOCUFF VISION® UK national and
UK(EP) patents (as amended) are valid and infringed by Cantel's
AmplifEYE® endoscopic device, and key design rights are valid and
infringed by AmplifEYE®. The patent and design rights had been
challenged by Cantel Medical (UK) Limited and Cantel (UK) Limited.

(Logo: http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg )

Peter Martin, COO of Norgine and Chair of the Arc Medical Design
Limited Board said: "We welcome the judgement and our resounding
success, recognising the strong protection for both ENDOCUFF® and
ENDOCUFF VISION®. This decision validates our confidence in the
intellectual property portfolio protecting our products. We will
always vigorously defend our intellectual property and will initiate
legal proceedings where appropriate."

ENDOCUFF VISION® is a single use device attached at the end of the
colonoscope that gives an optimal view of the entire colon by
retracting folds during withdrawal.

Notes to Editors:

About the UK Case No. HP-2016-000047

On Friday 23 February 2018 the High Court of Justice England and
Wales, Patents Court ruled that:Arc Medical Design Limited won on all
counts:

- Arc Medical Design Limited's ENDOCUFF and ENDOCUFF VISION UK
national patent 2478081 and UK(EP) patent 2575590, as amended, are
valid and infringed;
- its ENDOCUFF VISION Registered Community Design 002523191-0001 is
valid and infringed, its ENDOCUFF Registered Community Design
001856121-0001 is valid but not infringed; and
- its UK unregistered design rights in ENDOCUFF and ENDOCUFF VISION
will be infringed from the date of the judgment.
- The judgment is for the UK market.

View the full media release on http://www.norgine.com/media

Media Contact:

Isabelle Jouin, T: [phone]

Follow us @norgine

ots Originaltext: Norgine
Im Internet recherchierbar: http://www.presseportal.de